🔗 Share this article

As the US continues making historic changes to its vaccine schedules, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccinations during the global health crisis and has focused upon potential deaths after Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to announce radical revisions to the pediatric vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a major change that would place the US at odds with many the international standard with no evidence for benefit. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Høeg is scheduled to address the audience at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to lead the division this calendar year.

A New Direction at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending some childhood vaccine recommendations in the US to become more like Denmark, a nation with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – typically the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent track record in pharmaceutical research, regulation or administrative roles, which has been standard for past directors of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Former heads of the center would “grasp laws and regulations and the research of medication creation”, commented Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who headed the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock pointed out.

“Many people just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be supervised,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative component to the job, which oversees over 5,000 employees. “It’s a huge management job, if you execute it properly,” the former official said.

Response and Contentious Initiatives

In response to concerns about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among agency officials on vaccines, a representative responded that the “concerns rely on flawed presumptions”.

“Her resume is consistent with the duties of her job,” the spokesperson explained, pointing to the time Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's recently launched priority voucher program, a controversial one-day therapy clearance system that apparently worried her predecessors. “By what process are these therapies being picked for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, aside from shots.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if problematic, past, some experts observe. She published a research paper using non-validated public submissions to determine the frequency of heart inflammation following Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are more dangerous than they are.

Among her “wish list” for the incoming administration featured revising guidelines for novel immunizations and ending “non-essential” immunizations, she stated post-election on a online show. At the agency, Dr. Høeg has allegedly proposed preventing teenage boys from receiving Covid vaccinations.

“She is an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to retrofit the evidence in a very disingenuous, fraudulent manner,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|